Patients with moderate-to-severe T2DM and CKD were treated with insulin and an angiotensin receptor blocker or angiotensin-converting enzyme inhibitor at the maximum dose along with dulaglutide injected once weekly. The gene discussed is ACE; the disease is chronic kidney disease.